Translational Medicine Center, Zhengzhou Central Hospital, Affiliated to Zhengzhou University, Zhengzhou 450007, PR China.
Thyroid surgery, Zhengzhou Central Hospital, Affiliated to Zhengzhou University, Zhengzhou 450007, PR China.
Future Oncol. 2018 Dec;14(29):3015-3022. doi: 10.2217/fon-2018-0416. Epub 2018 Jul 10.
To investigate the expression level of lncRNA MALAT1 in papillary thyroid cancer (PTC) and evaluate its clinical diagnostic value as a biomarker in PTC.
MALAT1 lncRNA expression in tissues was detected by qRT-PCR. The diagnostic value of MALAT1 as a biomarker in PTC was evaluated with receiver operating characteristics.
MALAT1 expression was upregulated in PTC tissues compared with paired corresponding noncancerous tissues. We also found that upregulated MALAT1 expression was correlated with tumor size, lymph node metastases (p = 0.011) and WHO disease stage. The area under the curve was 0.6320, 0.7192, 0.7089 and 0.7000 for PTC, lymph node metastasis, extrathyroidal extension and WHO disease stage prediction, respectively.
Our finding suggests that MALAT1 may exert oncogenic function in PTC and may be a potential diagnostic marker for this cancer.
研究长链非编码 RNA MALAT1 在甲状腺乳头状癌（PTC）中的表达水平，并评估其作为 PTC 生物标志物的临床诊断价值。
通过 qRT-PCR 检测组织中 MALAT1 lncRNA 的表达。利用受试者工作特征曲线评估 MALAT1 作为 PTC 生物标志物的诊断价值。
与配对的相应非癌组织相比，PTC 组织中 MALAT1 的表达上调。我们还发现，上调的 MALAT1 表达与肿瘤大小、淋巴结转移（p=0.011）和世卫组织疾病分期相关。对于 PTC、淋巴结转移、甲状腺外侵犯和世卫组织疾病分期预测，曲线下面积分别为 0.6320、0.7192、0.7089 和 0.7000。
我们的研究结果表明，MALAT1 可能在 PTC 中发挥致癌作用，并且可能是这种癌症的潜在诊断标志物。
